FibroGen, Inc. (NASDAQ:FGEN) Short Interest Update

FibroGen, Inc. (NASDAQ:FGEN) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 3,440,000 shares, a drop of 11.8% from the November 15th total of 3,900,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the days-to-cover ratio is presently 2.9 days.

FibroGen Trading Up 7.1 %

NASDAQ:FGEN traded up $0.02 on Tuesday, reaching $0.35. The stock had a trading volume of 1,422,219 shares, compared to its average volume of 2,117,156. The company has a 50-day moving average of $0.35 and a 200 day moving average of $0.58. The stock has a market cap of $35.08 million, a P/E ratio of -0.26 and a beta of 0.82. FibroGen has a 12-month low of $0.18 and a 12-month high of $2.93.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same quarter last year, the firm posted ($0.52) EPS. On average, equities analysts predict that FibroGen will post -0.86 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. StockNews.com initiated coverage on FibroGen in a research report on Monday. They set a “hold” rating on the stock. William Blair reissued a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th.

Institutional Trading of FibroGen

A number of hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC boosted its stake in FibroGen by 34.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after acquiring an additional 860,854 shares during the last quarter. Doheny Asset Management CA bought a new position in shares of FibroGen during the second quarter worth about $48,000. XTX Topco Ltd acquired a new position in FibroGen in the second quarter worth about $424,000. Sei Investments Co. increased its holdings in FibroGen by 38.4% in the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 41,442 shares during the last quarter. Finally, Point72 DIFC Ltd raised its stake in FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.